Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EYPT

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.

MarketBeat · May 26

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.

Benzinga · Oct 15, 2025

Breakout Momentum Plays You May Not Know About

Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.

MarketBeat · Jun 6, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Small-Cap Stocks Under $20 With Over 220% Upside Potential

Wall Street is forecasting multibagger returns from these two small-cap biotech stocks over the next year.

Barchart · Aug 4, 2024

EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. This agreement expands the collaboration between EyePoint and Equinox Sciences, LLC, a Betta Pharmaceuticals affiliate established in February 2020. EyePoint will retain global ophthalmic rights for EYP-1901 in the…

Benzinga · May 4, 2022

Recap: EyePoint Pharmaceuticals Q1 Earnings

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC. Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will replace the existing approximately…

Benzinga · Mar 9, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Macular Degeneration

61 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.